相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparison of Effect Sizes Associated With Biomarkers Reported in Highly Cited Individual Articles and in Subsequent Meta-analyses
John P. A. Ioannidis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Biospecimen Reporting for Improved Study Quality (BRISQ)
Helen M. Moore et al.
JOURNAL OF PROTEOME RESEARCH (2011)
Invasive Breast Cancer
Robert W. Carlson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2011)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
C. Davies et al.
LANCET (2011)
Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
Susan M. Domchek et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Sources of Bias in Specimens for Research About Molecular Markers for Cancer
David F. Ransohoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
American Society of Clinical Oncology Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors
Timothy D. Gilligan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Clinical Trials With Biomarkers: Design Issues
Boris Freidlin et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Gordon J. S. Rustin et al.
LANCET (2010)
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group
Steven M. Teutsch et al.
GENETICS IN MEDICINE (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Benefits and harms of prostate-specific antigen screening for prostate cancer: An evidence update for the US preventive services task force
Kenneth Lin et al.
ANNALS OF INTERNAL MEDICINE (2008)
Commentary: Hormone Receptor Testing in Breast Cancer: A Distress Signal from Canada
D. Craig Allred
ONCOLOGIST (2008)
How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design
David F. Ransohoff
JOURNAL OF CLINICAL EPIDEMIOLOGY (2007)
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
[Anonymous]
JOURNAL OF ONCOLOGY PRACTICE (2007)
The minimum information about a proteomics experiment (MIAPE)
Chris F. Taylor et al.
NATURE BIOTECHNOLOGY (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping
Federico Innocenti et al.
PHARMACOGENOMICS (2006)
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
Gershon Y. Locker et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting
James L. Khatcheressian et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Differential exoprotease activities confer tumor-specific serum peptidome patterns
J Villanueva et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
REporting recommendations for tumour MARKer prognostic studies (REMARK)
LM McShane et al.
BRITISH JOURNAL OF CANCER (2005)
Clinical trial designs for predictive marker validation in cancer treatment trials
DJ Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gene expression profiling of breast cancer: A new tumor marker
LJ van't Veer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments
KA Baggerly et al.
BIOINFORMATICS (2004)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
ND Kauff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations
TR Rebbeck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Use of proteomic patterns in serum to identify ovarian cancer
EF Petricoin et al.
LANCET (2002)
分享论文
